BACKGROUND: The mechanisms leading to hepatic injury in chronic hepatitis C virus (HCV) infection are only incompletely understood. Recent data propose a correlation of the intrahepatic expression of the CC chemokine RANTES and the degree of periportal and portal inflammatory liver damage. AIM: Here, we have studied the intrahepatic mRNA levels of CC chemokines RANTES together with that of other members of this chemokine family (MIP-1beta, MCP-1, and MCP-2) in chronic hepatitis C as compared with healthy controls. METHODS: Liver samples from 22 HCV-infected patients, nine individuals with primary biliary cirrhosis and from 12 normal controls were included into this study. Intrahepatic mRNA levels of CC chemokines RANTES, MIP-1beta, MCP-1, and MCP-2 were analyzed by a semi-quantitative reverse transcription/real-time polymerase chain reaction assay. RESULTS: In chronic HCV infection, intrahepatic RANTES mRNA levels were significantly higher than in non-infected controls (7.2-fold, p < 0.001) or in the disease control group (2.8-fold, p < 0.001) and higher levels of RANTES mRNA levels were observed in livers with an advanced stage of liver cell injury (histologic activity index > or = 6), although this difference was not statistically significant (p = 0.08). In contrast, mRNA levels of MIP-1beta (p = 0.021) and MCP-1 (p = 0.021) were significantly lower in HCV liver samples while MCP-2 expression was similar in all groups analyzed. CONCLUSION: The data support the concept of chemokines as mediators of liver cell injury in chronic hepatitis C.
BACKGROUND: The mechanisms leading to hepatic injury in chronic hepatitis C virus (HCV) infection are only incompletely understood. Recent data propose a correlation of the intrahepatic expression of the CC chemokine RANTES and the degree of periportal and portal inflammatory liver damage. AIM: Here, we have studied the intrahepatic mRNA levels of CC chemokines RANTES together with that of other members of this chemokine family (MIP-1beta, MCP-1, and MCP-2) in chronic hepatitis C as compared with healthy controls. METHODS: Liver samples from 22 HCV-infectedpatients, nine individuals with primary biliary cirrhosis and from 12 normal controls were included into this study. Intrahepatic mRNA levels of CC chemokines RANTES, MIP-1beta, MCP-1, and MCP-2 were analyzed by a semi-quantitative reverse transcription/real-time polymerase chain reaction assay. RESULTS: In chronic HCV infection, intrahepatic RANTES mRNA levels were significantly higher than in non-infected controls (7.2-fold, p < 0.001) or in the disease control group (2.8-fold, p < 0.001) and higher levels of RANTES mRNA levels were observed in livers with an advanced stage of liver cell injury (histologic activity index > or = 6), although this difference was not statistically significant (p = 0.08). In contrast, mRNA levels of MIP-1beta (p = 0.021) and MCP-1 (p = 0.021) were significantly lower in HCV liver samples while MCP-2 expression was similar in all groups analyzed. CONCLUSION: The data support the concept of chemokines as mediators of liver cell injury in chronic hepatitis C.
Authors: Arantxa Apolinario; Pedro L Majano; Eduardo Alvarez-Pérez; Alicia Saez; Carlos Lozano; Javier Vargas; Carmelo García-Monzón Journal: Am J Gastroenterol Date: 2002-11 Impact factor: 10.864
Authors: Kenneth J Simpson; Neil C Henderson; Cynthia L Bone-Larson; Nicholas W Lukacs; Cory M Hogaboam; Steven L Kunkel Journal: Clin Sci (Lond) Date: 2003-01 Impact factor: 6.124
Authors: G Fiore; I Angarano; L Caccetta; M Serrone; E Jirillo; O Schiraldi; S Antonaci Journal: Eur J Gastroenterol Hepatol Date: 1997-05 Impact factor: 2.566
Authors: C L Bone-Larson; K J Simpson; L M Colletti; N W Lukacs; S C Chen; S Lira; S L Kunkel; C M Hogaboam Journal: Immunol Rev Date: 2000-10 Impact factor: 12.988
Authors: Marie-Luise Berres; Rory R Koenen; Anna Rueland; Mirko Moreno Zaldivar; Daniel Heinrichs; Hacer Sahin; Petra Schmitz; Konrad L Streetz; Thomas Berg; Nikolaus Gassler; Ralf Weiskirchen; Amanda Proudfoot; Christian Weber; Christian Trautwein; Hermann E Wasmuth Journal: J Clin Invest Date: 2010-10-18 Impact factor: 14.808
Authors: Georgi Kirovski; Erwin Gäbele; Christoph Dorn; Lukas Moleda; Christoph Niessen; Thomas S Weiss; Hella Wobser; Doris Schacherer; Christa Buechler; Hermann E Wasmuth; Claus Hellerbrand Journal: Int J Clin Exp Pathol Date: 2010-08-02
Authors: Karla J Helbig; Andrew Ruszkiewicz; Robert E Lanford; Mark D Berzsenyi; Hugh A Harley; Shaun R McColl; Michael R Beard Journal: J Virol Date: 2008-11-05 Impact factor: 5.103
Authors: Andreas Nellen; Daniel Heinrichs; Marie-Luise Berres; Hacer Sahin; Petra Schmitz; Amanda E Proudfoot; Christian Trautwein; Hermann E Wasmuth Journal: PLoS One Date: 2012-05-04 Impact factor: 3.240